NCT05883995 is a clinical trial of Phage therapy requests in Bone Infection, sponsored by Hospices Civils de Lyon.

Who is sponsoring NCT05883995?

NCT05883995 is sponsored by Hospices Civils de Lyon.

What drugs are being tested in NCT05883995?

Interventions in NCT05883995: Phage therapy requests.

What condition does NCT05883995 study?

NCT05883995 studies Bone Infection.

Is NCT05883995 still recruiting?

NCT05883995 is currently recruiting now. Last updated 1 June 2023.

Last reviewed 2023-06-01 · How we verify

NCT05883995

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avis-PHAGEinLYON Clinic

Recruiting now Last updated 1 June 2023

What this trial tests

trial testing Phage therapy requests in Bone Infection in 1,500 participants. Currently enrolling.

Timeline

1 February 2023

Primary endpoint
1 February 2028

1 February 2029

Quick facts

Lead sponsor	Hospices Civils de Lyon
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,500
Start date	1 February 2023
Primary completion	1 February 2028
Estimated completion	1 February 2029
Sites	1 location across France

Drugs / interventions tested

Phage therapy requests

Conditions studied

Bone Infection — all drugs for Bone Infection →

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

Eligibility, any sex, with Bone Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Avis-PHAGEinLYON Clinic study is a single site non-interventional retrospective and prospective study, initiated by the Hospices Civils de Lyon. Population targeted are patients referred to the Hospices Civils de Lyon for a medical advice for a phage therapy from 2015 to 2028. The primary objective is to quantify the phage therapy requests received at the Hospices Civils de Lyon. 1500 patients will be included in the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Access to phage therapy at Hospices Civils de Lyon in 2022: Implementation of the PHAGEinLYON Clinic programme.
Ferry T, Bouar ML, Briot T, Roussel-Gaillard T, et al · · 2024 · cited 5× · PMID 39491599 · DOI 10.1016/j.ijantimicag.2024.107372

Verify or expand the search:

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05883995 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
Last refreshed: 1 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05883995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing